Spots Global Cancer Trial Database for SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
Official Title: A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer
Study ID: NCT04408898
Conditions
Interventions
Study Description
Brief Summary: This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A\*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic Phoenix, Phoenix, Arizona, United States
University of California San Diego, San Diego, California, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
Karmanos Cancer Insitute, Detroit, Michigan, United States
Providence Cancer Institute Franz Head and Neck Clinic, Portland, Oregon, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
West Virginia University Cancer Institute, Morgantown, West Virginia, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
